Extra-Pulmonary Neuroendocrine Carcinoma: Key Distinctions, Current Treatment, and Emerging Targets

Monday, June 23, 2025

12:00 PM (UTC-04:00) Eastern Time (US & Canada)

Thursday, June 26, 2025

12:30 PM (UTC-04:00) Eastern Time (US & Canada)

Duration
60 minutes

Credit Type
CME, AAPA, CNE, AANP, APA

Intended Learners

The proposed activity is intended for community and academic oncology healthcare professionals (HCPs) who care for patients with EP-NECs, including oncologists, gynecologic oncologists, gastrointestinal oncologists, oncology nurse practitioners (NPs) and physician assistants (PAs), radiologists, pathologists, and pharmacists; as well as allied HCPs who care for patients with EP-NECs.

Learning Objectives

Delineate the key differences between NETs and NECs, including their respective pathologic features, diagnostic criteria, treatment guidelines, and prognostic implications
Describe the role of DLL3 as an emerging target in the progression and prognosis of EP-NEC
Evaluate the current treatment landscape, most recent clinical trial data, and innovative advancements associated with available and emerging therapies for EP-NEC

Continuing Education

In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Note: This statement is not an indication of approved credits. Please visit the accreditation page for full accreditation details, including credit types and totals, for this activity.

Extra-Pulmonary Neuroendocrine Carcinoma: Key Distinctions, Current Treatment, and Emerging Targets

Speakers